What Vanda Pharmaceuticals Inc. told the SEC could break it.

Vanda's revenue is concentrated in a limited number of specialty pharmacies, specialty distributors and wholesalers — four major customers each accounted for more than 10% of total revenues in 2025 and together represented 76% of total revenues; loss of, or reduced purchasing by, any of these channel customers would materially disrupt revenue. (Customers not named in the filing, so recorded as concentration risk rather than named edges.)

“There were four major customers that each accounted for more than 10% of total revenues for 2025 and, as a group, represented 76% of total revenues for the year ended December 31, 2025.”

Vanda depends on single-source suppliers for critical raw materials and product-administration components, and relies on third parties for manufacturing (contract manufacturers), sales, distribution, medical affairs and clinical research; loss of a single-source supplier — or the lengthy, FDA-CMC-gated process of qualifying a new one — could delay clinical trials or prevent/delay commercialization.

“The Company depends on single source suppliers for critical raw materials for manufacturing, as well as other components required for the administration of its products. The loss of these suppliers could delay the clinical trials or prevent or delay commercialization of the products.”

Vanda's near-term product revenue depends on a small set of products (Fanapt, HETLIOZ, PONVORY) and on its ability to defend their patents from generic competition and to obtain adequate coverage and reimbursement from government and private payors; generic entry or reimbursement cuts on any key product would materially reduce revenue.

“Our ability to generate significant product revenue from sales of our commercial products both in the U.S. and abroad, in the near term will depend on, among other things, our ability to: defend our patents and intellectual property from generic competition; properly price and obtain adequate coverage and reimbursement of these products by go”

Vanda's growth depends on FDA decisions — including an unresolved jet-lag sNDA that drew a complete-response/hearing process — and even approved products face U.S. drug-pricing pressure: the company warns revenues may decline significantly due to the Medicare Part D benefit redesign, and the American Rescue Plan's removal of the Medicaid drug-rebate cap (effective 2024) further pressures pricing.

“Revenues may decline in future periods, potentially significantly, as a result of the Medicare Part D program benefit redesign.”